Literature DB >> 21204255

Endothelin-1- and isoproterenol-induced differential protein expression and signaling pathway in HL-1 cardiomyocytes.

Hye-Min Hong1, Eun Joo Song, Eulsik Oh, Mohammad Humayun Kabir, Cheolju Lee, Young Sook Yoo.   

Abstract

It is well known that the two chemical compounds endothelin-1 (ET-1) and isoproterenol (ISO) can individually induce cardiac hypertrophy through G protein-coupled receptors in cardiomyocytes. However, the cardiac hypertrophy signaling pathway activated by ET-1 and ISO is not well defined. Therefore, we investigated the protein expression profile and signaling transduction in HL-l cardiomyocyte cells treated with ET-1 and ISO. Following separation of the cell lysates by using 2-DE and silver staining, we identified 16 protein spots that were differentially expressed as compared to the controls. Of these 16 spots, three changed only after treatment with ET-1, whereas four changed only after treatment with ISO, suggesting that these two stimuli could induce different signaling pathways. In order to reveal the differences between ET-1- and ISO-induced signaling, we studied the different events that occur at each step of the signaling pathways, when selected biocomponents were blocked by inhibitors. Our results indicated that ET-1 and ISO used different pathways for phosphorylation of glycogen synthase kinase-3β (GSK3β). ET-1 mainly used the mitogen-activated protein kinase and phosphatidylinositol-3-kinase/AKT pathways to activate GSK3β, whereas under ISO stimulation, only the phosphatidylinositol-3-kinase/AKT pathway was required to trigger the GSK3β pathway. Furthermore, the strength of the GSK3β signal in ISO-induced cardiac hypertrophy was stronger than that in ET-1-induced cardiac hypertrophy. We found that these two agonists brought about different changes in the protein expression of HL-1 cardiomyocytes through distinct signaling pathways even though the destination of the two signaling pathways was the same.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21204255     DOI: 10.1002/pmic.201000018

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  9 in total

1.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

2.  Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.

Authors:  Xueying Tan; Jianping Li; Xinyue Wang; Nan Chen; Benzhi Cai; Gang Wang; Hongli Shan; Deli Dong; Yanju Liu; Xingda Li; Fan Yang; Xin Li; Peng Zhang; Xueqi Li; Baofeng Yang; Yanjie Lu
Journal:  Int J Biol Sci       Date:  2011-04-07       Impact factor: 6.580

3.  The structural basis for the negative regulation of thioredoxin by thioredoxin-interacting protein.

Authors:  Jungwon Hwang; Hyun-Woo Suh; Young Ho Jeon; Eunha Hwang; Loi T Nguyen; Jeonghun Yeom; Seung-Goo Lee; Cheolju Lee; Kyung Jin Kim; Beom Sik Kang; Jin-Ok Jeong; Tae-Kwang Oh; Inpyo Choi; Jie-Oh Lee; Myung Hee Kim
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

4.  Endothelin A receptor antagonist, atrasentan, attenuates renal and cardiac dysfunction in Dahl salt-hypertensive rats in a blood pressure independent manner.

Authors:  Mohammed A Samad; Ui Kyoung Kim; Joshua J Kang; Qingen Ke; Peter M Kang
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

5.  Quantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.

Authors:  Benben Song; Yashu Liu; Toufan Parman; Shufeng Liu; Jennifer K Miller; Xiaohua Liu; Mary J Tanga; Jon Mirsalis
Journal:  J Proteome Res       Date:  2014-11-07       Impact factor: 4.466

6.  Cardiac thromboxane A2 receptor activation does not directly induce cardiomyocyte hypertrophy but does cause cell death that is prevented with gentamicin and 2-APB.

Authors:  Chad D Touchberry; Neerupma Silswal; Vladimir Tchikrizov; Christopher J Elmore; Shubra Srinivas; Adil S Akthar; Hannah K Swan; Lori A Wetmore; Michael J Wacker
Journal:  BMC Pharmacol Toxicol       Date:  2014-12-17       Impact factor: 2.483

Review 7.  Biology of the cardiac myocyte in heart disease.

Authors:  Angela K Peter; Maureen A Bjerke; Leslie A Leinwand
Journal:  Mol Biol Cell       Date:  2016-07-15       Impact factor: 4.138

Review 8.  Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery.

Authors:  Eunji Shin; Kyung Soo Ko; Byoung Doo Rhee; Jin Han; Nari Kim
Journal:  Integr Med Res       Date:  2014-10-13

9.  The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes.

Authors:  Wendy Rosales; Fernando Lizcano
Journal:  Front Genet       Date:  2018-02-09       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.